|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9656
|
|
pubmed:dateCreated |
2008-12-22
|
|
pubmed:abstractText |
Calcitonin gene-related peptide (CGRP) probably has a role in migraine pathophysiology, and antagonism of its receptors might provide treatment without the vasoconstrictor effects of triptans. We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Azepines,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitonin Gene-Related Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/N-(6-(2,3-difluorophenyl)-2-oxo-1-(2...,
http://linkedlifedata.com/resource/pubmed/chemical/Oxazolidinones,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Calcitonin Gene-Related...,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Receptor Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Tryptamines,
http://linkedlifedata.com/resource/pubmed/chemical/zolmitriptan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:AssaidChristopherC,
pubmed-author:DodickDavid WDW,
pubmed-author:FanXiaoyinX,
pubmed-author:FerrariMichel DMD,
pubmed-author:FromanSamarS,
pubmed-author:GaletVinceV,
pubmed-author:HoTony WTW,
pubmed-author:KoppenHilleH,
pubmed-author:KostJamesJ,
pubmed-author:LeibenspergerHeatherH,
pubmed-author:LinesChristopherC,
pubmed-author:WinnerPaul KPK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
372
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2115-23
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19036425-Adult,
pubmed-meshheading:19036425-Azepines,
pubmed-meshheading:19036425-Calcitonin Gene-Related Peptide,
pubmed-meshheading:19036425-Dose-Response Relationship, Drug,
pubmed-meshheading:19036425-Double-Blind Method,
pubmed-meshheading:19036425-Female,
pubmed-meshheading:19036425-Humans,
pubmed-meshheading:19036425-Imidazoles,
pubmed-meshheading:19036425-Male,
pubmed-meshheading:19036425-Migraine Disorders,
pubmed-meshheading:19036425-Oxazolidinones,
pubmed-meshheading:19036425-Receptors, Calcitonin Gene-Related Peptide,
pubmed-meshheading:19036425-Serotonin Receptor Agonists,
pubmed-meshheading:19036425-Severity of Illness Index,
pubmed-meshheading:19036425-Tryptamines
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
|
|
pubmed:affiliation |
Merck Research Laboratories, North Wales, PA 19454-1099, USA. tony_ho@merck.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
